Scroll to explore the milestones and achievementsthat have made Mallinckrodt the leading pharmaceuticals company it is today.
1840 Emil Mallinckrodt purchases a plot of land in the Bremen area of St. Louis, Missouri, which becomes the site of the first Mallinckrodt factory.
1867 Emil's sons, Gustavo, Otto and Edward establish G. Mallinckrodt and Company, in order to supply local pharmacists with much-needed drugs. It is the only chemical company west of Philadelphia.
1880 Becomes the leading supplier of chemicals for the emerging photography industry
1882 Incorporates in Missouri as Mallinckrodt Chemical Works
1883 Introduces employee healthcare benefits for the first time
1884 Establishes its first office in New York City
1889 Becomes the leading U.S. producer of anhydrous ammonia, an important chemical used in the refrigeration industry
1898 Begins production of two chemicals that would go on to play a key role in the history of pain relief: morphine and codeine
1904 Holds an exhibit at the St. Louis World’s Fair, an international event which covered industry, science and technology; a staggering 20 million people attended
1913 Begins production of barium sulfate, a key component used in contrast media-enhanced images, for x-ray diagnoses
1914 Perfects a new method for storing ether — the first modern anesthetic — significantly reducing impurities, and improving stability
1924 Introduces iodeikon to the scientific community, the first x-ray contrast media used for gall bladder visualization
1942 Purified and provided all of the uranium oxide used by the Manhattan Project (U.S.), which developed the world’s first self-sustaining nuclear chain reaction
1950 Introduces UROKON™ SODIUM, the leading contrast media used to diagnose kidney disease
1954 Mallinckrodt sells stock to the public for the first time
1960 Installs the first computer system aimed at servicing Mallinckrodt customers, the RCA 301 with 40kB RAM
1962 Acquires Van Pelt & Brown, entering into the "ethical pharmaceutical market," which includes antispasmodic and cardiovascular products
1966 Acquires Nuclear Consultants, Inc., of Maryland Heights, Missouri, giving Mallinckrodt a foothold into the radiopharmaceutical business for nuclear medicine imaging
1971 Mallinckrodt begins production of para-aminophenol (PAP) and N-acetyl-p-aminophenol (APAP), in response to worldwide demand for a product by the name of Tylenol®
1973 U.S. Food and Drug Administration (FDA) approves Ultra-Technekow™ FM Technetium Tc 99m generator
1979 Responds to the Three Mile Island nuclear reactor accident near Middletown, Pennsylvania, with the production of more than 250,000 saturated potassium iodide doses
1982 Avon acquires Mallinckrodt
1986 Acquired by International Minerals and Chemical Corporation which became the IMCERA Group, Inc. in 1990
1989 Launches non-ionic x-ray contrast media in vials and pre-filled syringes
1992 Begins contrast media production in Europe by opening a plant in Dublin, Ireland
1994 FDA approves Octreoscan™ (kit for the preparation of indium In-III pentetreotide). IMCERA Group, Inc. becomes known as Mallinckrodt Group.
1995 Launches the company's first generic pharmaceutical
1996 Acquires Graham Laboratories drug dosage forms plant in Hobart, New York, as well as imaging device maker Liebel-Flarsheim, in Cincinnati, Ohio
2000 Mallinckrodt is acquired by Tyco International
2001 Expands the branded pharmaceuticals portfolio by acquiring five new products
2007 Tyco Healthcare separates from Tyco International and renames itself as Covidien, an independent company
2008 Launches the Kit for the Preparation of Technetium Tc 99m Sestamibi Injection (Tc 99m Sestamibi)
2010 Expands pain franchise with the launch of three new pain products
2011 Launches a line of transdermal patches for pain relief
2012 Extends pain franchise with a co-promoted product. Acquires an immediate release branded opioid. Acquires CNS Therapeutics and its intrathecal therapy products. Receives FDA approval for the first generic of a widely prescribed attention-deficit hyperactivity disorder (ADHD) product.
2013 Mallinckrodt Pharmaceuticals spins off from Covidien, becoming an independent, $2 billion public company that develops, manufactures, markets, and distributes specialty pharmaceutical products and diagnostic imaging agents.
2014 Receives FDA approval for two new drugs. Acquires Cadence Pharmaceuticals and its IV analgesic product, establishing the company's hospital-focused pharmaceutical platform. Acquires Questcor Pharmaceuticals and enters the autoimmune and rare diseases space.
2015 Acquires Ikaria, Inc., expanding into the neonatal critical care arena and adding pipeline drug focused on a rare disease. Acquires Therakos, Inc. and its immunotherapy product line, further expanding hospital platform. Divests contrast media and delivery systems business.
2016 Acquires three hemostasis products from The Medicines Company. Acquires Stratatech Corp. and its investigational skin substitute products. Receives FDA approval for a generic version of an ADHD/narcolepsy medication. Opens global corporate headquarters in Staines-upon-Thames, United Kingdom.
2017 Divests nuclear imaging business. Divests intrathecal therapies business. Receives FDA approval for a generic version of a widely used pain medication.